Wingstop (NASDAQ:WING – Free Report) had its target price trimmed by Wedbush from $390.00 to $355.00 in a research report ...
Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...
Research analysts at Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for Tri Pointe Homes in a research ...
However, Wedbush Securities sees the reaction as overblown. Analyst Dan Ives and his team argue that instead of hurting Palantir, the proposed cuts could actually work in its favor. With the ...
Wedbush made a splash on Tuesday with the announcement that it was entering the ever-growing exchange-traded fund market. With more than 7K ETFs listed globally, collectively managing over $10T in ...
Wedbush analyst Robert Driscoll last night initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $18 price target ...
Wedbush LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions ...
Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their ...
Investment analysts at Wedbush cut their FY2025 EPS estimates for RH in a research report issued on Tuesday, February 18th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback